文献速递甲状腺疾病

甲状腺激素在常染色体显性多囊肾病中展现预后与治疗潜力

Thyroid Hormones Exhibit Promising Prognostic and Therapeutic Potential in Autosomal Dominant Polycystic Kidney Disease.
PubMed 文献 · Thyroid · 2026-06-15

本研究探讨甲状腺激素(THs)在常染色体显性多囊肾病(ADPKD)中的作用及药理调节的治疗潜力。患者来源肾上皮细胞构建3D多囊管测试THs抗囊作用,PCK大鼠体内评估T4疗效,90例ADPKD患者血清THs与eGFR相关性分析。结果显示T4通过αvβ3整合素抑制囊生长,PCK大鼠中T4降低肾重和巨囊面积,患者rT3与肾功能负相关、fT3正相关。

要点

  • T4通过αvβ3整合素调控增殖、代谢和铁死亡通路抑制囊肿生长
  • PCK大鼠中T4降低肾重并显著减少巨囊面积
  • ADPKD患者rT3与肾功能负相关、fT3正相关

核心结论

  • 甲状腺激素参与ADPKD进展,是潜在的预后标志物和治疗靶点。
  • THs通过调控多条致病通路,可能提供多靶点策略减少囊肿生长并保护肾功能。

研究设计与样本

  • 使用患者来源肾上皮细胞构建3D多囊管,测试THs及其类似物的抗囊生成效应。
  • 在ADPKD动物模型PCK大鼠中体内评估T4减少囊肿形成和延缓疾病进展的疗效。
  • 在REORIENTED临床研究(NCT05646420)入组的90例ADPKD患者中检测血清THs水平并与eGFR进行相关性分析。

主要发现

  • T4通过结合αvβ3整合素,调控增殖、代谢和铁死亡通路抑制囊肿生长。
  • PCK大鼠中T4给药降低肾重并显著减少巨囊面积(%:Vehicle 9.255 ± 2.654 vs. T4 1.945 ± 0.850,p < 0.05)。
  • 总体ADPKD患者中,rT3水平与肾功能呈负相关(R2 = 0.159,r = -0.397,p < 0.001)。
  • fT3水平与肾功能呈正相关(R2 = 0.110,r = 0.332,p < 0.01)。

关键数值与推荐

  • PCK大鼠巨囊面积(%):Vehicle 9.255 ± 2.654 vs. T4 1.945 ± 0.850,p < 0.05。
  • 90例ADPKD患者rT3与肾功能:R2 = 0.159,r = -0.397,p < 0.001。
  • 90例ADPKD患者fT3与肾功能:R2 = 0.110,r = 0.332,p < 0.01。

临床怎么用

  • 血清rT3和fT3水平可能作为ADPKD疾病严重程度的预后参考指标。
  • 甲状腺激素及其类似物可能作为ADPKD多靶点治疗策略,支持个性化激素治疗开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by progressive cyst development and renal dysfunction. While thyroid hormones (THs) are known to regulate key pathways in various kidney diseases, their role in ADPKD pathobiology and therapeutic potential remains unexplored. Here, we aimed to elucidate the role of THs in ADPKD and evaluate whether their pharmacological modulation could serve as a therapeutic strategy. METHODS: Patient-derived renal epithelial cells were used to engineer 3D polycystic tubules and to test the anti-cystogenic effects of THs and their analogs. The therapeutic efficacy of thyroxine (T4) in reducing cyst formation and delaying disease progression was assessed in vivo using PCK rats, an animal model of ADPKD. Lastly, serum THs levels were measured in 90 ADPKD patients enrolled in the REORIENTED clinical study and correlated with estimated glomerular filtration rate to explore their clinical relevance (Clinical Trial Gov NCT05646420). RESULTS: Mechanistically, thyroxine inhibits cyst growth by modulating proliferative, metabolic and ferroptotic pathways through αvβ3 integrin binding. In PCK rats, an animal model of ADPKD, T4 administration decreased kidney weight and significantly reduced macrocystic area (%, Vehicle 9.255 ± 2.654 vs. T4 1.945 ± 0.850, p < 0.05). Clinical data from ADPKD patients showed that altered TH serum levels correlate with disease severity: in the overall population of the study reverse triiodothyronine (rT3, a T3's metabolite) levels inversely correlate with renal function (R2 = 0.159, r = -0.397, p < 0.001), while free triiodothyronine (fT3) levels show a positive correlation (R2 = 0.110, r = 0.332, p < 0.01). CONCLUSIONS: This study reveals that THs contribute to ADPKD progression and identifies them as potential prognostic and therapeutic agents. By modulating multiple pathogenic pathways, THs may offer a novel, multi-targeted approach to reduce cyst growth and preserve renal function. These findings further support the development of personalized, hormone-based treatments and more refined stratification in the clinical management of ADPKD.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lavecchia AM, Locatelli L, Trillini M, et al. Thyroid Hormones Exhibit Promising Prognostic and Therapeutic Potential in Autosomal Dominant Polycystic Kidney Disease. Thyroid. 2026. PMID: 42296046. doi:10.1177/10507256261460200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。